Use of cannabidiol products in Canada, United States, Australia, Aotearoa New Zealand, United Kingdom and Germany: products, sources and reasons for use

The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: A systematic review and meta-analysis

10.1016/s2215-0366(26)00015-5 · doi-reference

CBD (cannabidiol) product attitudes, knowledge, and use among young adults

10.1080/10826084.2020.1729201 · doi-reference

The prevalence of cannabidiol (CBD) use in North America and Europe: A meta-analysis

10.1111/add.70360 · doi-reference

The effectiveness and safety of cannabidiol in non-seizure-related indications: A systematic review of published randomized clinical trials

10.1007/s40290-022-00446-8 · doi-reference

Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis

10.1016/j.expneurol.2022.114238 · doi-reference

Cannabidiol: A review of clinical efficacy and safety in epilepsy

10.1016/j.pediatrneurol.2019.03.014 · doi-reference

Implementation of the medicinal cannabis scheme in New Zealand: six emerging trends

10.26635/6965.6666 · doi-reference

Medicinal cannabis–The Green Fairy phenomenon

10.1071/ch21001 · doi-reference

Odds ratios—Current best practice and use

10.1001/jama.2018.6971 · doi-reference

Cannabidiol for moderate–severe insomnia: A randomized controlled pilot trial of 150 mg of nightly dosing

10.5664/jcsm.10998 · doi-reference

Cannabidiol (CBD) products for pain: Ineffective, expensive, and with potential harms

10.1016/j.jpain.2023.10.009 · doi-reference

Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems

10.1186/s42238-021-00061-5 · doi-reference

Effectiveness of cannabidiol to manage chronic pain: A systematic review

10.1016/j.pmn.2023.10.002 · doi-reference

Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition

10.1111/dar.13444 · doi-reference

A systematic review of cannabidiol dosing in clinical populations

10.1111/bcp.14038 · doi-reference

Legal and regulatory issues governing cannabis and cannabis-derived products in the United States

10.3389/fpls.2019.00697 · doi-reference

Access to cannabidiol without a prescription: A cross-country comparison and analysis

10.1016/j.drugpo.2020.102935 · doi-reference

Safety and side effects of cannabidiol, a cannabis sativa constituent

10.2174/157488611798280924 · doi-reference

Expert advice for prescribing cannabis medicines for patients with epilepsy—Drawn from the Australian clinical experience

10.1111/bcp.15262 · doi-reference

Using cannabis and CBD to sleep: An updated review

10.1007/s11920-024-01564-7 · doi-reference

Efficacy and safety of cannabidiol in epilepsy: A systematic review and meta-analysis: S. Lattanzi et al

10.1007/s40265-018-0992-5 · doi-reference

Beyond the hype-who uses cannabidiol for self-medication–and why: A cross-sectional study in Germany

10.1186/s42238-025-00341-4 · doi-reference

Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis

10.1016/j.socscimed.2019.06.005 · doi-reference

Use of internet panels to conduct surveys

10.3758/s13428-015-0617-9 · doi-reference

Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis

10.1016/j.psychres.2024.116049 · doi-reference

Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study

10.1016/j.drugpo.2020.102698 · doi-reference

Understanding medical cannabis use internationally: Why definitions and context matter

10.1111/add.70117 · doi-reference

Cannabidiol drug interaction considerations for prescribers and pharmacists

10.1080/17512433.2022.2142114 · doi-reference

Use and perceptions of cannabidiol products in Canada and in the United States

10.1089/can.2020.0093 · doi-reference

Usage and health perception of cannabidiol-containing products among the population in Germany: A descriptive study conducted in 2020 and 2021

10.1186/s12889-023-17142-0 · doi-reference

CBD products that resemble tobacco products enter traditional retail outlets

10.1136/tobaccocontrol-2019-055452 · doi-reference

Cannabidiol in foods and food supplements: Evaluation of health risks and health claims

10.3390/nu17030489 · doi-reference

Self-reported reasons for medical and nonmedical cannabis use in Australia: A cross-sectional analysis of the International Cannabis Policy Study 2023

10.1016/j.drugalcdep.2026.113124 · doi-reference

A cross-sectional study of cannabidiol users

10.1089/can.2018.0006 · doi-reference

Prevalence of cannabidiol use and correlates in US adults

10.1016/j.dadr.2024.100289 · doi-reference

Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials

10.1038/s41386-020-0667-2 · doi-reference

The emerging role of cannabidiol (CBD) products; A survey exploring the public's use and perceptions of CBD

10.1002/ptr.7232 · doi-reference

Medical cannabis: Regulatory review in United States, European Union and United Kingdom

10.1016/j.jflm.2025.102947 · doi-reference

Recreational cannabidiol: Awareness, prevalence of use, and associated factors in a representative sample of the German population

10.1080/10826084.2022.2083175 · doi-reference

Consumer perception, knowledge, and uses of cannabidiol

10.9740/mhc.2023.10.217 · doi-reference